Digestive Diseases and Sciences

, Volume 57, Issue 4, pp 1112–1113 | Cite as

Thalidomide Treatment in Cirrhotic Patients with Severe Anemia Secondary to Vascular Malformations

  • Antonio Garrido Serrano
  • Rafael León
  • Manuel Sayago
  • Jose Luis Márquez
Correspondence
First Online:

Keywords

Vascular Endothelial Growth Factor Octreotide Thalidomide NASH Hepatic Encephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Ge ZZ, Chen HM, Gao YJ et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141:1629–1637.e4.Google Scholar
  2. 2.
    Kamalaporn P, Saravanan R, Cirocco M, May G, Kortau P, Candel G. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. Eur J Gastroenterol Hepatol. 2009;21:1347–1350.PubMedCrossRefGoogle Scholar
  3. 3.
    Karajeh MA, Hursltone DP, Stephenson TJ, Ray-Chaudhuri D, Gleeson DC. Refractory bleeding from portal hypertensive gastropathy: a further novel role for thalidomide therapy? Eur J Gastroenterol Hepatol. 2006;18:545–548.PubMedCrossRefGoogle Scholar
  4. 4.
    Craanen ME, van Triest B, Verjeihen RH, Mulder CJ. Thalidomide in refractory haemorrhagic radiation induced proctitis. Gut. 2006;55:1371–1372.PubMedCrossRefGoogle Scholar
  5. 5.
    Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy. 2006;38:1036–1039.PubMedCrossRefGoogle Scholar
  6. 6.
    Molina-Infante J, Perez-Gallardo B. Somatostatin analogues for bleeding gastrointestinal angiodysplasias: when should thalidomide be prescribed? Dig Dis Sci. 2011;56:266–267.PubMedCrossRefGoogle Scholar
  7. 7.
    Tekkesin N, Taga Y, Sav A, Almaata I, Ibrisim D. Induction of HGF and VEGF in hepatic regeneration after hepatotoxin-induced cirrhosis in mice. Hepatogastroenterology. 2011;58:971–979.PubMedGoogle Scholar
  8. 8.
    Hanje A, Shamp JL, Thomas FB, Meis GM. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy. 2006;26:1018–1022.PubMedCrossRefGoogle Scholar
  9. 9.
    Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol. 2006;12:6955–6960.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Antonio Garrido Serrano
    • 1
  • Rafael León
    • 1
  • Manuel Sayago
    • 1
  • Jose Luis Márquez
    • 1
  1. 1.Department of Digestive DiseasesUniversity Hospital Virgen del RocíoSevilleSpain

Personalised recommendations